Published in J Bone Miner Res on October 01, 2011
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis | NCT00089791
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genet (2012) 1.64
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int (2015) 1.46
The burden of illness of osteoporosis in Canada. Osteoporos Int (2012) 1.34
The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone (2014) 0.94
The fragile elderly hip: mechanisms associated with age-related loss of strength and toughness. Bone (2014) 0.86
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. Osteoporos Int (2014) 0.82
The burden of illness of osteoporosis in Canadian men. J Bone Miner Res (2012) 0.82
New insights into treatment of osteoporosis in postmenopausal women. RMD Open (2015) 0.76
Role of cortical bone in hip fracture. Bonekey Rep (2017) 0.75
Combined oral administration of bovine collagen peptides with calcium citrate inhibits bone loss in ovariectomized rats. PLoS One (2015) 0.75
Bone Density Screening and Re-screening in Postmenopausal Women and Older Men. Curr Osteoporos Rep (2015) 0.75
Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis. Exp Ther Med (2015) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study. J Am Geriatr Soc (2005) 6.54
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol (2003) 5.04
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med (2005) 3.39
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Mapping of a major locus that determines telomere length in humans. Am J Hum Genet (2004) 3.33
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med (2008) 3.20
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc (2009) 3.09
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc (2002) 3.03
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc (2005) 3.02
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Common variants near TERC are associated with mean telomere length. Nat Genet (2010) 2.98
Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med (2011) 2.98
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res (2004) 2.92
A drug burden index to define the functional burden of medications in older people. Arch Intern Med (2007) 2.84
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
Informed Consent. N Engl J Med (2017) 2.56
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 2.55
Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab (2003) 2.54
Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat (2005) 2.53
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol (2008) 2.48
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med (2014) 2.48
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48